CLAIMS

1. Use of dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da in the manufacture of a medicament for inducing angiogenesis in an ischemic tissue or organ in a subject.

2. Use of dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da in the manufacture of a medicament for increasing blood flow in a subject suffering from ischemia.

3. The use according to claim 2, wherein the medicament is for increasing blood flow in an ischemic tissue or organ of said subject.

4. Use of dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da in the manufacture of a medicament for vascularizing ischemic tissue in a subject.

5. The use according to any of the claims to 1 to 4, wherein said average molecular weight is within a range of 2 000 and 10 000 Da.

6. The use according to claim 5, wherein said average molecular weight is within a range of 3 000 and 10 000 Da.

7. The use according to claim 6, wherein said average molecular weight is within a range of 3 500 and 9 500 Da.

8. The use according to claim 7, wherein said average molecular weight is within a range of 4 500 and 7 500 Da.

9. The use according to claim 8, wherein said average molecular weight is within a range of 4 500 and 5 500 Da.

10. The use according to any of the claims 1 to 9, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content in a range from 15 to 20 %.

11. The use according to claim 10, wherein said average sulfur content is about 17 %.

12. The use according to any of the claims 1 to 4, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has a number average molecular weight (M_n) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 2000 Da.

13. The use according to claim 12, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has on average 5.1 glucose units and an average sulfate number per glucose unit of 2.6 to 2.7.

14. The use according to any of the claims 1 to 13, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, is formulated as an aqueous injection solution.

15. The use according to any of the claims 1 to 14, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, is formulated to be administered at a dosage in a range from 0.05 to 50 mg/kg of body weight of said subject, preferably from 0.05 to 30 mg/kg of body weight of said subject, and more preferably from 0.1 to 15 mg/kg or 0.1 to 10 mg/kg body weight of said subject.

16. The use according to any of the claims 1 to 15, wherein said subject is a human subject suffering from a disease, disorder or medical condition causing ischemia in the body.

17. The use according to claim 16, wherein said disease, disorder or medical condition is selected from a group consisting of wound healing, peripheral ischemia, preferably ischemia following transplantation of organ, tissue and/or cells, peripheral arterial disease, limb ischemia, restless leg, Raynaud's syndrome, sickle cell disease or thromboangiitis obliterans; coronary ischemia, preferably congestive heart failure, myocardial infarction or a coronary arterial disease; an ischemic disease in children, preferably a perinatal or neonatal disease, neonatal hypoxic or ischemic brain injury, asphyxia encephalopathy, cerebral palsy; ischemia in central nervous system, preferably traumatic brain injury, temporal arteritis, hypoxia caused by multiple sclerosis, stroke, amyotrophic lateral sclerosis; muscular dystrophic diseases; ischemia caused by thrombotic, hemorrhagic or traumatic injuries.

18. The use according to any of the claims 1 to 17, wherein said pharmaceutically acceptable salt is a sodium salt of dextran sulfate.